Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Department of control of Neglected Tropical Diseases, World Health Organization, Geneva, Switzerland.
PLoS Negl Trop Dis. 2018 Mar 13;12(3):e0006250. doi: 10.1371/journal.pntd.0006250. eCollection 2018 Mar.
The control or elimination of neglected tropical diseases (NTDs) has targets defined by the WHO for 2020, reinforced by the 2012 London Declaration. We estimated the economic impact to individuals of meeting these targets for human African trypanosomiasis, leprosy, visceral leishmaniasis and Chagas disease, NTDs controlled or eliminated by innovative and intensified disease management (IDM).
A systematic literature review identified information on productivity loss and out-of-pocket payments (OPPs) related to these NTDs, which were combined with projections of the number of people suffering from each NTD, country and year for 2011-2020 and 2021-2030. The ideal scenario in which the WHO's 2020 targets are met was compared with a counterfactual scenario that assumed the situation of 1990 stayed unaltered. Economic benefit equaled the difference between the two scenarios. Values are reported in 2005 US$, purchasing power parity-adjusted, discounted at 3% per annum from 2010. Probabilistic sensitivity analyses were used to quantify the degree of uncertainty around the base-case impact estimate.
The total global productivity gained for the four IDM-NTDs was I$ 23.1 (I$ 15.9 -I$ 34.0) billion in 2011-2020 and I$ 35.9 (I$ 25.0 -I$ 51.9) billion in 2021-2030 (2.5th and 97.5th percentiles in brackets), corresponding to US$ 10.7 billion (US$ 7.4 -US$ 15.7) and US$ 16.6 billion (US$ 11.6 -US$ 24.0). Reduction in OPPs was I$ 14 billion (US$ 6.7 billion) and I$ 18 billion (US$ 10.4 billion) for the same periods.
We faced important limitations to our work, such as finding no OPPs for leprosy. We had to combine limited data from various sources, heterogeneous background, and of variable quality. Nevertheless, based on conservative assumptions and subsequent uncertainty analyses, we estimate that the benefits of achieving the targets are considerable. Under plausible scenarios, the economic benefits far exceed the necessary investments by endemic country governments and their development partners. Given the higher frequency of NTDs among the poorest households, these investments represent good value for money in the effort to improve well-being, distribute the world's prosperity more equitably and reduce inequity.
世界卫生组织(WHO)为 2020 年制定了控制或消除被忽视的热带病(NTDs)的目标,并在 2012 年的伦敦宣言中得到了加强。我们估计了在创新性和强化疾病管理(IDM)下,达到人类非洲锥虫病、麻风病、内脏利什曼病和恰加斯病这些目标对个人的经济影响,这些疾病都是可以控制或消除的 NTDs。
系统文献回顾确定了与这些 NTDs 相关的生产力损失和自付费用(OPPs)的信息,这些信息与 2011-2020 年和 2021-2030 年每个 NTD 患者的数量、国家和年份的预测相结合。将达到世卫组织 2020 年目标的理想情况与假设 1990 年情况保持不变的反事实情况进行了比较。经济利益等于两种情况之间的差异。以 2005 年的美元计价,按购买力平价调整,从 2010 年起每年贴现 3%。概率敏感性分析用于量化基本情况影响估计的不确定性程度。
在 2011-2020 年期间,四种 IDM-NTDs 的全球总生产力收益为 231 亿美元(159-340 亿美元),在 2021-2030 年期间为 359 亿美元(250-519 亿美元)(括号内为 2.5%和 97.5%分位数),相当于 107 亿美元(74-157 亿美元)和 166 亿美元(116-240 亿美元)(括号内为 2.5%和 97.5%分位数)。同期 OPPs 的减少量为 140 亿美元(67 亿美元)和 180 亿美元(104 亿美元)。
我们在工作中面临着重要的限制,例如没有找到麻风病的 OPPs。我们不得不结合来自不同来源、不同背景和不同质量的有限数据。尽管如此,根据保守的假设和随后的不确定性分析,我们估计实现这些目标的好处是相当可观的。在合理的情况下,经济效益远远超过了流行国家政府及其发展伙伴的必要投资。鉴于 NTDs 在最贫困家庭中更为普遍,这些投资在改善福祉、更公平地分配世界繁荣和减少不平等方面具有很高的性价比。